Developer docs
API playgroundTry for free, no card

Search company profiles

AGEPHA Pharma

Full company profile

uuid000blf7

Namestring
AGEPHA Pharma
Company typeenum
Private
Founded yearint
1947
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSenec
HQ citystring
Senec
Markets served

Serves global market

Keyword5 values
pharmaceutical products, cardiovascular drugs, repurposed medications, prescription therapeutics, specialty pharmaceuticals
Industry3 codes
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Cardiovascular Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Drug Sales
TypeOne Time License
Description

AGEPHA Pharma generates revenue through the sale of proprietary pharmaceutical drugs. The company received FDA approval for Lodoco (colchicine-based) for cardiovascular disease in 2023, representing a repurposed drug with premium pricing strategy.

drugpatentwatch.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Marketing or Sales, Personnel, Operations, Technology or R&D, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

AGEPHA Pharma is a specialty pharmaceutical company that develops and commercializes prescription drugs, with a primary focus on its FDA-approved cardiovascular product Lodoco (colchicine 0.5 mg), the first anti-inflammatory medication approved for reducing the risk of heart attack, stroke, coronary revascularization, and cardiovascular death in patients with established atherosclerotic disease or multiple risk factors. The company also operates in adjacent areas including dietary supplements, ophthalmology, dermatology, and vitamins and minerals.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

AGEPHA Pharma is a specialty pharmaceutical company with a focused portfolio centered on its FDA-approved product Lodoco, a colchicine-based cardiovascular treatment. The company operates in the repurposed drug space, bringing established molecules to new therapeutic indications through regulatory approval.

Product and service1 record
1Lodoco (colchicine 0.5 mg tablet)
CategoryCardiovascular Pharmaceuticals
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-06-23
Description

Close-Up Intl provides AI-powered CRM technology deployed across AGEPHA Pharma's U.S. sales force. The platform offers real-time healthcare professional insights, digital omnichannel engagement capabilities, Direct-to-Practitioner sampling functionality, and performance intelligence designed to enhance field productivity and sales force effectiveness. The collaboration is intended to help AGEPHA Pharma increase productivity and more effectively manage its business in the competitive U.S. pharmaceutical market.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Pfizer is a broad incumbent with established cardiovascular and cardiometabolic franchises and dominant relationships with U.S. cardiologists. It is comparable as a competitive backdrop for Lodoco's U.S. launch.

TypeDirect peer
Description

ANI is a U.S. specialty pharma company that markets branded and generic prescription products, including cardiovascular and specialty care medicines. It is comparable to AGEPHA as a smaller specialty pharma commercializing niche prescription products through targeted physician channels.

TypeEmerging player
Description

BioXcel is a clinical-stage company working on repurposed and reformulated therapies in immunology and neuroscience. It is comparable to AGEPHA in applying a repurposing model to bring differentiated therapeutics to market.

TypeBroad incumbent
Description

AstraZeneca has a major cardiovascular franchise (e.g., Brilinta, Farxiga) and is a dominant incumbent in cardiovascular risk reduction. It is comparable as a competitor prescriber-side for Lodoco within cardiology.

TypeDirect peer
Description

Takeda markets Colcrys (colchicine), the established colchicine brand in the U.S. It is the most direct competitor to AGEPHA's Lodoco since both products use colchicine as the active ingredient, though for different indications.

TypeDirect peer
Description

Hikma is a specialty pharmaceutical company with branded and generic product portfolios including cardiovascular therapies. It is comparable to AGEPHA in business model — a specialty pharma commercializing differentiated prescription products to physicians.

TypeBroad incumbent
Description

Novartis operates a large cardiovascular portfolio (e.g., Entresto, Leqvio). It is comparable to AGEPHA as a broad incumbent shaping the competitive landscape where Lodoco is being commercialized.

TypeEmerging player
Description

TherapeuticsMD is a specialty pharmaceutical company commercializing branded prescription products in focused therapeutic areas. It is comparable to AGEPHA as a small-cap specialty pharma targeting specific prescriber segments with differentiated branded products.

TypeEmerging player
Description

Apnimed is a clinical-stage pharma developing repurposed drugs for sleep apnea and related indications. It is comparable to AGEPHA as a smaller company pursuing a repurposed-drug strategy into new therapeutic indications.

TypeRegional player
Description

Zentiva is a European specialty and generic pharmaceutical company based in the Czech Republic/Slovakia region. It is comparable to AGEPHA as a Central European specialty pharma with overlapping therapeutic areas and similar geographic roots.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AGEPHA Pharma

Cardiovascular Pharmaceuticalsagephapharma.com

AGEPHA Pharma firmographics

Firmographics
Name
AGEPHA Pharma
Website
https://agephapharma.com
Company type
Private
Founded year
1947
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

AGEPHA Pharma industry classification

Industry
Product category
Cardiovascular Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Pharmaceutical products
  • Cardiovascular drugs
  • Repurposed medications
  • Prescription therapeutics
  • Specialty pharmaceuticals

Where AGEPHA Pharma is headquartered

Location

Headquarters

HQ city
Senec

Markets served

AGEPHA Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Marketing or Sales, Personnel, Operations, Technology or R&D, Supply Chain

Revenue model

  1. Pharmaceutical Drug Sales: AGEPHA Pharma generates revenue through the sale of proprietary pharmaceutical drugs. The company received FDA approval for Lodoco (colchicine-based) for cardiovascular disease in 2023, representing a repurposed drug with premium pricing strategy.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

AGEPHA Pharma product offering

Product offering

Core offering

AGEPHA Pharma is a specialty pharmaceutical company that develops and commercializes prescription drugs, with a primary focus on its FDA-approved cardiovascular product Lodoco (colchicine 0.5 mg), the first anti-inflammatory medication approved for reducing the risk of heart attack, stroke, coronary revascularization, and cardiovascular death in patients with established atherosclerotic disease or multiple risk factors. The company also operates in adjacent areas including dietary supplements, ophthalmology, dermatology, and vitamins and minerals.

Product overview

AGEPHA Pharma is a specialty pharmaceutical company with a focused portfolio centered on its FDA-approved product Lodoco, a colchicine-based cardiovascular treatment. The company operates in the repurposed drug space, bringing established molecules to new therapeutic indications through regulatory approval.

Differentiator

Problem solved

Functional benefit

Products and services

  • Lodoco (colchicine 0.5 mg tablet)

Companies that use AGEPHA Pharma

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

AGEPHA Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

AGEPHA Pharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Close-Up IntlcoreTechnology or Integration · 23 June 2026Close-Up Intl provides AI-powered CRM technology deployed across AGEPHA Pharma's U.S. sales force. The platform offers real-time healthcare professional insights, digital omnichannel engagement capabilities, Direct-to-Practitioner sampling functionality, and performance intelligence designed to enhance field productivity and sales force effectiveness. The collaboration is intended to help AGEPHA Pharma increase productivity and more effectively manage its business in the competitive U.S. pharmaceutical market.

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

AGEPHA Pharma competitors and assessment

Company assessment

Broad incumbents

  • Pfizer: Pfizer is a broad incumbent with established cardiovascular and cardiometabolic franchises and dominant relationships with U.S. cardiologists. It is comparable as a competitive backdrop for Lodoco's U.S. launch.
  • AstraZeneca: AstraZeneca has a major cardiovascular franchise (e.g., Brilinta, Farxiga) and is a dominant incumbent in cardiovascular risk reduction. It is comparable as a competitor prescriber-side for Lodoco within cardiology.
  • Novartis: Novartis operates a large cardiovascular portfolio (e.g., Entresto, Leqvio). It is comparable to AGEPHA as a broad incumbent shaping the competitive landscape where Lodoco is being commercialized.

Direct peers

  • ANI Pharmaceuticals: ANI is a U.S. specialty pharma company that markets branded and generic prescription products, including cardiovascular and specialty care medicines. It is comparable to AGEPHA as a smaller specialty pharma commercializing niche prescription products through targeted physician channels.
  • Takeda Pharmaceutical: Takeda markets Colcrys (colchicine), the established colchicine brand in the U.S. It is the most direct competitor to AGEPHA's Lodoco since both products use colchicine as the active ingredient, though for different indications.
  • Hikma Pharmaceuticals: Hikma is a specialty pharmaceutical company with branded and generic product portfolios including cardiovascular therapies. It is comparable to AGEPHA in business model — a specialty pharma commercializing differentiated prescription products to physicians.

Emerging players

  • BioXcel Therapeutics: BioXcel is a clinical-stage company working on repurposed and reformulated therapies in immunology and neuroscience. It is comparable to AGEPHA in applying a repurposing model to bring differentiated therapeutics to market.
  • TherapeuticsMD: TherapeuticsMD is a specialty pharmaceutical company commercializing branded prescription products in focused therapeutic areas. It is comparable to AGEPHA as a small-cap specialty pharma targeting specific prescriber segments with differentiated branded products.
  • Apnimed: Apnimed is a clinical-stage pharma developing repurposed drugs for sleep apnea and related indications. It is comparable to AGEPHA as a smaller company pursuing a repurposed-drug strategy into new therapeutic indications.

Regional players

  • Zentiva: Zentiva is a European specialty and generic pharmaceutical company based in the Czech Republic/Slovakia region. It is comparable to AGEPHA as a Central European specialty pharma with overlapping therapeutic areas and similar geographic roots.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

AGEPHA Pharma social profiles

Digital presence

AGEPHA Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AGEPHA Pharma leadership team

Management profile

Number of profiles

AGEPHA Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AGEPHA Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AGEPHA Pharma

What does AGEPHA Pharma do?

AGEPHA Pharma is a specialty pharmaceutical company that develops and commercializes prescription drugs, with a primary focus on its FDA-approved cardiovascular product Lodoco (colchicine 0.5 mg), the first anti-inflammatory medication approved for reducing the risk of heart attack, stroke, coronary revascularization, and cardiovascular death in patients with established atherosclerotic disease or multiple risk factors. The company also operates in adjacent areas including dietary supplements, ophthalmology, dermatology, and vitamins and minerals.

When was AGEPHA Pharma founded?

AGEPHA Pharma was founded in 1947. It employs 11 to 50 people.

Where is AGEPHA Pharma based?

AGEPHA Pharma is headquartered in Senec.

How does AGEPHA Pharma make money?

One revenue line is on record: pharmaceutical Drug Sales.

Who are AGEPHA Pharma's main competitors?

Broad incumbents on record are Pfizer, AstraZeneca and Novartis. Direct peers are ANI Pharmaceuticals, Takeda Pharmaceutical and Hikma Pharmaceuticals. Emerging players are BioXcel Therapeutics, TherapeuticsMD and Apnimed. Zentiva is listed as a regional player.

Does AGEPHA Pharma have an API?

No public API is recorded for AGEPHA Pharma.

What industry is AGEPHA Pharma in?

AGEPHA Pharma's product category is Cardiovascular Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity), with a secondary code of HLAIACAG, Cardiology & Vascular Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals